Released Nov 4, 2025, before the open
10-Q filed Nov 4, 2025, 35 days after period end · 0001193125-25-263670
Q3 2025 · 10-Q
Revenue$205.63M$205.63M +4.6% vs Q3 2024+1.2% vs Q2 2025
Net Income-$22.80M-$22.80M N/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.57-$0.57 N/M vs Q3 2024N/M vs Q2 2025
Gross Profit$148,523,000+10.0%
Operating Income-$17,046,000N/M
Operating Cash Flowderived$12,402,000+6.3%
Free Cash Flowderived$2,498,000−60.7%
Margins · derived
Gross margin72.2%+3.5 pt vs Q3 2024
Operating margin-8.3%+1.3 pt vs Q3 2024
Net margin-11.1%+2.8 pt vs Q3 2024
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $205.63M | $196.61M | $184.01M | $114.00M |
| Net Income | -$22.80M | -$27.39M | -$28.86M | -$10.72M |
| EPS Diluted | -$0.57 | -$0.71 | -$0.77 | -$0.53 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR